The human cytochrome P450 1A2 is an important drug metabolizing and procarcinogen activating enzyme. An experimental study found that a peripheral mutation, F186L, at ∼26 Å away from the enzyme’s ...

The CYP17A1 inhibitors market is projected to attain USD 1,350 million by 2025, expanding at a robust CAGR of 8.5% between 2025 and 2032, supported by strong pipeline activity, expanded ...

CYP17A1 Inhibitors Market to Reach USD 1.35 Billion by 2025, Fueled by Advancements in Prostate Cancer Therapeutics The CYP17A1 inhibitors market is projected to attain USD 1,350 million by 2025, ...

CYP17A1 inhibition blocks two critical steps in testosterone biosynthesis: the conversion of pregnenolone to 17-OH-pregnenolone and the conversion of 17-OH-pregnenolone to dehydroepiandrosterone.